AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis StudyBenzinga • 10/20/26
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinibBusiness Wire • 10/19/26
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research • 10/16/26
RBC keeps AstraZeneca at ‘outperform' ahead of AVANZAR lung cancer trialProactive Investors • 10/15/26
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting TranscriptSeeking Alpha • 10/12/26
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says CitiProactive Investors • 10/12/26
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyGlobeNewsWire • 10/08/26
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPRNewsWire • 10/08/26
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter resultsProactive Investors • 10/07/26
Citi raises AstraZeneca target to £186 as tozorakimab prospects improveProactive Investors • 10/06/26
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investmentCNBC • 10/05/26
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, MassachusettsBusiness Wire • 10/05/26
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosZacks Investment Research • 10/05/26